CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 39 enrolled
Drug / intervention
Teriparatide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01473602
NCT01473602Phase 3Completed

Second Study of the Effect of Teriparatide on Femoral Neck Fracture Healing

Eli Lilly and Company·interventional·Posted Nov 17, 2011·Updated Apr 16, 2015

In Brief

A Phase 3 clinical trial evaluating Teriparatide, Placebo, and 2 other interventions for Femur Neck Fracture. Completed, enrolled 39 participants across 75 sites in 14 countries.

Detailed Summary

The purpose of this study is to see whether teriparatide, given for 6 months versus placebo, will improve the healing of hip (femoral neck) fractures that are repaired during surgery using certain types of orthopedic screws. The study will enroll men and postmenopausal women at least 50 years of age with a recent hip (femoral neck) fracture caused by low-trauma (for example, fall from standing height or less).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Croatia, France, Germany, Greece, Hungary, India, Netherlands, Poland, Romania, South Korea, Switzerland, Turkey (Türkiye), United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 17, 2011
Enrollment StartJan 1, 2012
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.6 years ago

Interventions

Teriparatidedrug

Administered by SC injection

Placebodrug

Administered by SC injection

Calcium supplementationdietary

Administered orally

Vitamin D supplementationdietary

Administered orally